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Introduction
The use of menopausal hormone therapy (HT) to prevent bone loss has 
long been considered one of the major indications for its use. Following 
the publication of the Women’s Health Initiative (WHI) study in 20031 the 
role of HT in the prevention of chronic diseases such as osteoporosis and 
cardiovascular disease has been questioned. Subsequently the majority 
of guidelines emanating from menopause societies recommended that 
the primary role of HT, be it oestrogen only (E) or oestrogen with progestin 
(E/P), should be the alleviation of the symptoms of early menopause 
and that it should be used in the lowest effective dose for the shortest 
possible time. In the years since the publication of the WHI results there 
have been publications from sub-studies and re-analyses of the WHI as 
well as publications on the use of different products and different modes 
of delivery of oestrogen and progestin. The current status of HT therefore 
needs to be re-evaluated in the light of these more recent publications.
Hormone therapy and bone density
Oestrogen administration, both with and without a progestin, results 
in an increase of bone mineral density (BMD). In the Postmenopausal 
Oestrogen/Progestin Intervention (PEPI) trial,2 a double-blind placebo-
controlled study, women were randomised to receive placebo, 
conjugated equine oestrogen (CEE) or a combination of CEE and 
medroxyprogesterone acetate (MPA). By 36 months those patients on 
placebo had lost an average of 2.8% of spinal BMD and 2.2% of hip 
BMD. Those compliant with any active regimen gained approximately 
5.1% BMD in the spine and 2.3% in the hip.
Hormone therapy and prevention of fractures
The WHI study was the definitive study demonstrating the anti-fracture 
efficacy of HT.3 There was a reduction in both vertebral and hip fractures: 
the relative risks (RR) for fracture in patients on E/P compared to 
placebo was 0.65(CI 0.46-0.92) and 0.67(CI 0.47-0.96) for spine and hip 
respectively. It is important to realise that the patients in the WHI study 
were not necessarily osteoporotic or considered at high risk for fracture, 
adding more weight to the significant reduction of fractures, particularly 
in the hip, where many studies using other osteoporotic agents had been 
unable to show such a reduction.
However, the prevention of fractures was not a primary endpoint of 
the WHI study. The primary endpoints were myocardial infarction and 
coronary death, and the initial publication reported a significant increase 
in these events. In a later publication,4 after adjudication of events, the 
increase in coronary events did not reach statistical significance. The 
results of the WHI study also showed an increase in thrombotic strokes, 
venous thromboembolism and breast cancer (not significant), as well 
as a reduction in colorectal cancer. The authors of the publication on 
osteoporosis concluded, however, that despite the significant reduction 
in fractures there is no place for the use of HT in the treatment of 
osteoporosis in asymptomatic patients. This conclusion was based on 
the use of an index the authors termed the global index of health risk, 
which was purported to estimate the balance of health versus risk. The 
authors concluded that the overall health risk was greater with the use 
of HT in patients at low, moderate and high risk for fracture. 
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A further problem with the use of HT for the prevention or treatment of 
osteoporosis is that long-term use would be necessary if the population 
at most risk for fracture, namely elderly patients, is to be protected 
against fracture. The need to continue with HT on a long-term basis is 
supported by the findings of numerous studies that suggest that the bone 
protective effects of HT are lost soon after discontinuation. The most 
compelling data comes from an analysis of the National Osteoporosis 
Risk Assessment (NORA) study.5 This study investigated bone mineral 
density and one-year fracture risk in relation to duration of hormone 
therapy (HT) use and time since discontinuation in 170  852 women. 
As regards density, current users had the highest T-scores. Women 
who had stopped HRT more than five years previously, regardless of 
duration of use, had T-scores similar to those who have never used 
HRT. Current users of HT had a 21 to 29% lower risk for fracture over 
one year than non-users. This protection was lost within five years of 
discontinuation. Increased duration of therapy did not appear to confer 
any greater protection. Studies published by Lindsay6 and Ascott-Evans7 
have supported the finding of rapid loss of the density gained whilst on 
HT when the therapy is discontinued.
A re-appraisal of hormone therapy use
There remain many proponents of the use of HT for osteoporosis. The 
International Menopause Society (IMS) supports a re-evaluation of HT 
for the prevention and treatment of osteoporosis8 and state that HT 
can be considered a first-line therapy in women under 60 years.9 The 
global index of health risk as used in the WHI study is not a validated 
health risk assessment tool. In addition, the overall health risks in the 
WHI study apply to a specific population of women whose average age 
was 63 years. These risks may therefore not be applicable to a younger 
population of women. A re-analysis of the combined results of the E 
only arm and the E/P arm of the WHI study10 investigated cardiac risk 
in patients aged 50 to 59 years at initiation of HT and also considered 
the effects on cardiac events with early intervention as opposed to late 
intervention with HT. This re-analysis indicated a trend towards a lower 
risk with early intervention, but this did not reach statistical significance. 
What did reach statistical significance, however, was a 30% lower 
overall mortality compared to placebo in the group of women starting HT 
within 10 years of the onset of menopause. The cardioprotective effect 
of HT with early intervention has also been shown in a re-analysis of the 
Nurses’ Health Study.11
The issue of rapid bone loss after cessation of therapy is not yet fully 
resolved as not all studies have shown accelerated loss of density after 
discontinuation of therapy. In the PEPI study,12 495 women had bone 
density measured for the three years of the study and then annually 
for four years thereafter. The mean annual loss after stopping HT was 
1.01% in the spine and 1.04% in the hip. There was no significant 
difference as to annual loss when comparing the women who had been 
on HT and those who had not. Christiansen,13 in a three-year study of 
94 women, showed a 3.7% increase in bone mineral content (BMC) in 
the forearm in patients taking HT compared to a loss of 5.7% in those 
on placebo. After completion of the study the annual loss was similar 
in both groups. Similar long-term protection was found in a study of 
347 women who had participated in four placebo-controlled HT trials.14 
Follow-up DXA examinations were performed at five, 10 and 15 years 
after the end of the studies. BMD remained 5% higher in previous users 
of HT and the RR for fracture in this group was 0.48 (CI 0.26-0.88). An 
interesting finding in this study was that there were fast bone losers in 
both the placebo group and the group who had been on HT and that 
the rate of bone loss affected fracture risk. The fast bone losers in the 
placebo group had the highest risk of fracture. The fast bone losers in 
the group who had been on HT had a risk equal to the slow bone losers 
who had been on placebo. The group with the lowest risk of fracture was 
the HT group who remained slow bone losers after completion of HT.
The risk profile of HT may also be less with lower doses and different 
modes of delivery. The findings of the WHI study and other prospective 
studies on HT, such as the HERS studies,15,16 resulted in a reassessment 
of dose, type of hormone use and mode of delivery. Risk for thrombosis 
appears to be low or not increased at all with the use of transdermal 
oestrogen.17,18 Transdermal therapy has advantages over oral therapy as 
regards its effect on surrogate markers of cardiovascular risk.19 Given the 
necessary size and duration of a prospective study that would compare 
oral and transdermal delivery systems on cardiac events, it is highly 
unlikely that such a study will take place. However, the Kronos Early 
Oestrogen Prevention Study (KEEPS),20 a five-year prospective study, will 
allow comparison of oral and transdermal HT on carotid intima-media 
thickness and coronary artery calcium. Recruitment started in 2005 and 
will close out in 2010. Protection against bone loss occurs with the use 
of lower doses of oestrogen than those used in the WHI study. Even 
ultra-low dose transdermal oestrogen in the form of a 14 µg patch has 
been shown to protect against bone loss in the majority of patients.21 
The use of less androgenic progestins may have a more beneficial 
cardiovascular profile.22 Prospective fracture prevention studies using 
lower doses of oestrogen, comparing different modes of delivery and 
using different progestins would allow a more conclusive comparison 
of the risk versus benefit profile of HT compared to other drugs used to 
treat osteoporosis. Given the results of the studies discussed above that 
suggested that after cessation of HT the rate of bone loss differs from 
person to person, further studies are needed on the use of markers of 
bone resorption to identify fast bone losers. This may allow for patients 
who have been treated with HT in early menopause to be switched to 
alternative treatment modalities which will result in ongoing protection 
against bone loss and fracture.
Tibolone and osteoporosis
No discussion of the place of hormone therapy in the treatment of 
osteoporosis is complete without considering the place of tibolone. 
Tibolone is a selective tissue oestrogenic activity regulator (STEAR) 
which exerts its effect on bone via its 3α and 3β metabolites that 
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stimulate the oestrogen receptor. The Long-Term Intervention on 
Fractures with Tibolone (LIFT) study,23 a placebo-controlled randomised 
controlled study on women between the ages of 60 and 85, showed 
a significant reduction in vertebral (RR 0.55, CI 0.41-0.74) and non-
vertebral (RR 0.74, CI 0.58-0.93) fractures. The study was terminated 
prematurely due to an increase in stroke risk in the tibolone group (RR 
2.19, CI 1.14-4.23). The authors concluded that tibolone was effective in 
preventing vertebral fractures in postmenopausal women but that due 
to the risk of stroke it should not be used in elderly women and women 
with risk factors for stroke. 
Conclusions
Based on the data from the more recent WHI re-analyses, HT is safe 
when used in early menopause. Therefore, in the younger symptomatic 
patient, where the primary indication is the alleviation of the symptoms 
of menopause, HT will prevent bone loss and decrease the risk of 
fractures and should therefore be considered as one of the first-line 
therapies in these patients. As the primary indication for the use of HT 
in these patients is symptom relief the therapy would be used for as 
long as needed for this indication. When used correctly soon after the 
onset of menopause, the risks are minimal. In the asymptomatic patient, 
the issue is not as clear. However, HT can be considered along with 
drugs such as strontium ranelate, the bisphosphonates and raloxifene 
in the younger asymptomatic patient considered to be at high risk for 
fracture. The side effect and risk profile of each drug would need to be 
considered and discussed with each patient to allow for individualised 
therapy. Where HT is used, be it in the symptomatic or asymptomatic 
patient, when the therapy is terminated alternative therapies need to be 
initiated in patients still considered to be at high risk for fracture. The 
duration of use will be determined by a regular reassessment of the 
balance of benefit and risk. Those patients who do not need alternative 
treatments should have follow-up bone density assessments so that fast 
bone losers can be identified and treated appropriately. 
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